RecruitingNot Applicable

Effectiveness And Impact Of Nirsevimab In Chile (NIRSE-CL)

Chile160,000 participantsStarted 2024-04-01

Plain-language summary

The Nirse-CL study is a collaborative effort between the Ministry of Health of Chile, Instituto Sistemas Complejos de Ingeniería (ISCI), and the Faculty of Medicine of the University of Chile. The primary aim is to determine the effectiveness of the monoclonal antibody nirsevimab in preventing RSV infection in infants based on the integrated analysis of several national databases before, during, and after the implementation of a universal immunization program. The impact of the program on RSV-related health outcomes will also be determined.

Who can participate

Age range4 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects born between October 1st, 2023, to September 31st, 2024. * Subjects born with 29 weeks of gestational age (wga) or less who were born between July 1st, 2023 and October 1st, 2023 * Subjects born with Bronchopulmonary Dysplasia (BPD), 32 or less wga and/or a birth weight less than 1·5 kgs born between April 1st, 2023 and October 1st, 2023. Exclusion Criteria: * No specific criteria has been reported

What they're measuring

LRTI

Timeframe: from April 2024 to October 2024

Trial details

NCT IDNCT06511687

SponsorInstituto Sistemas Complejos de Ingeniería

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10-01

Contact for this trial

Leonardo Basso, PhD in Business Administration

56 962295601 l.basso@isci.cl

View on ClinicalTrials.gov More RSV trials